Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.55 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP8 | P40818 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16887852 | 0.87 | SMN1; SMN2 (0.49) | IDO1KDM4EHPGDSMN1; SMN2USP8 | |
| SCHEMBL24499470 | 0.78 | NPC1 (0.51) | IDO1TDO2KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL7816254 | 0.75 | IDO1 (0.79) | IDO1TDO2 | |
| SCHEMBL6237073 | 0.74 | POLB (0.58) | IDO1TDO2POLBALDH1A1RXFP1 | |
| SCHEMBL20867489 | 0.74 | SMN1; SMN2 (0.39) | KDM4EHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL15045587 | 0.74 | USP8 (0.49) | KDM4EHPGDSMN1; SMN2USP8USP7 | |
| SCHEMBL28365240 | 0.73 | IDO1 (0.60) | IDO1TDO2 | |
| SCHEMBL12327994 | 0.73 | LMNA (0.42) | KDM4EHPGDSMN1; SMN2USP8USP7 | |
| SCHEMBL28361454 | 0.73 | IDO1 (0.61) | IDO1TDO2USP8USP7 | |
| SCHEMBL28365313 | 0.73 | IDO1 (0.74) | IDO1TDO2KDM4EALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710230-A | Naphtho [2,3-d ] imidazole-4, 9-dione derivative used as positive electrode of organic lithium ion battery and preparation method thereof | 常州大学 | 2023-02-24 | — | — | CN | claimed |
| US-20230101042-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | U.S. DEPARTMENT OF ENERGY | 2023-03-30 | — | — | US | disclosed |
| CN-110680813-B | Use of naphthoquinone derivatives as IDO1 and/or TDO inhibitors | 北京大学 | 2023-03-10 | — | — | CN | disclosed |
| US-20220185826-A1 | Tandem Carbene Phosphors | THE UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-06-16 | — | — | US | disclosed |
| US-20220181562-A1 | Tandem-Carbene Phosphors | THE UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| CN-110680813-A | Use of naphthoquinone derivatives as IDO1 and/or TDO inhibitors | 北京大学 | 2020-01-14 | — | — | CN | disclosed |
| US-20170077418-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-0876356-B1 | USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF | INNOTHERA SA LAB (FR) | 2001-10-31 | — | — | EP | disclosed |
| US-6262095-B1 | TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA | LABORATOIRE INNOTHERA (FR) | 2001-07-17 | — | — | US | disclosed |
| US-6174918-B1 | INHIBITING TUMOR CELL GROWTH SENSITIVE TO NAPHTHOQUINONE DERIVATIVE IN MAMMAL BY ADMINISTERING 2,3-DISUBSTITUTED NAPHTHOQUINONE COMPOUND | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-01-16 | — | — | US | disclosed |
| WO-1997030022-A1 | NAPHTHOQUINONE ANTITUMOR COMPOUND AND METHOD | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170077418-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | EPCAM, L1CAM, LAGE3 | IDO1 3719/4885TDO2 1506/4885KDM4E 2425/4885 |
| US-20220185826-A1 | Tandem Carbene Phosphors | OCIAD1, CCND2, OCIAD2 | IDO1 455/4885TDO2 132/4885KDM4E 4580/4885 |
| US-20220181562-A1 | Tandem-Carbene Phosphors | OCIAD2, OCIAD1, DUOX2 | IDO1 638/4885TDO2 827/4885KDM4E 4540/4885 |
| US-20230101042-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, AOC2 | IDO1 2179/4885TDO2 3025/4885KDM4E 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.